The role of BST2/tetherin in infection with the feline retroviruses

Other literature type, Article English OPEN
Dietrich, Isabelle ; Hosie, Margaret J. ; Willett, Brian J. (2011)

Pathogenic retroviral infections of mammals have induced the evolution of cellular anti-viral restriction factors and have shaped their biological activities. This intrinsic immunity plays an important role in controlling viral replication and imposes a barrier to viral cross-species transmission. Well-studied examples of such host restriction factors are TRIM5α, an E3 ubiquitin ligase that binds incoming retroviral capsids in the cytoplasm via its C-terminal PRY/SPRY (B30.2) domain and targets them for proteasomal degradation, and APOBEC3 proteins, cytidine deaminases that induce hypermutation and impair viral reverse transcription. Tetherin (BST-2, CD317) is an interferon-inducible transmembrane protein that potently inhibits the release of nascent retrovirus particles in single-cycle replication assays. However, whether the primary biological activity of tetherin in vivo is that of a restriction factor remains uncertain as recent studies on human tetherin suggest that it is unable to prevent spreading infection of human immunodeficiency virus type 1 (HIV-1). The feline tetherin homologue resembles human tetherin in amino acid sequence, protein topology and anti-viral activity. Transiently expressed feline tetherin displays potent inhibition of feline immunodeficiency virus (FIV) and HIV-1 particle release. However, stable ectopic expression of feline tetherin in a range of feline cell lines has no inhibitory effect on the growth of either primary or cell culture-adapted strains of FIV. By comparing and contrasting the activities of the felid and primate tetherins against their respective immunodeficiency-causing lentiviruses we may gain insight into the contribution of tetherins to the control of lentiviral replication and the evolution of lentiviral virulence.
  • References (33)
    33 references, page 1 of 4

    Abada, P., Noble, B., Cannon, P.M., 2005. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J. Virol. 79, 3627-3638.

    Ackley, C.D., Yamamoto, J.K., Levy, N., Pedersen, N.C., Cooper, M.D., 1990. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J. Virol. 64, 5652-5655.

    Aguiar, R.S., Peterlin, B.M., 2008. APOBEC3 proteins and reverse transcription. Virus Res. 134, 74-85.

    Mangeat, B ., Turelli, P., Caron, G., Friedli, M., Perrin, L., Trono, D., 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103.

    100. Sakai, H., Shibata, R., Sakuragi, J., Sakuragi, S., Kawamura, M., Adachi, A., 1993. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J. Virol. 67, 1663-1666.

    101. Sakuma, T., Noda, T., Urata, S., Kawaoka, Y., Yasuda, J., 2009. Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 83, 2382-2385.

    102. Sauter, D., Schindler, M., Specht, A., Landford, W.N., Münch, J., Kim, K.A., Votteler, J., Schubert, U., Bibollet-Ruche, F., Keele, B.F., Takehisa, J., Ogando, Y., Ochsenbauer, C., Kappes, J.C., Ayouba, A., Peeters, M., Learn, G.H., Shaw, G., Sharp, P.M., Bieniasz, P., Hahn, B.H., Hatziioannou, T., Kirchhoff, F., 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6, 409-421.

    103. Sebastian, S., Luban, J. 2005. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2, 40.

    104. Sheehy, A.M., Gaddis, N.C., Choi, J.D., Malim, M.H., 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature, 418, 646-650.

    105. Sheehy, A.M., Gaddis, N.C., Malim, M.H., 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9, 1404-1407.

  • Metrics
    No metrics available
Share - Bookmark